Navigation Links
ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
Date:3/31/2008

ADVENTRX Presents Results at Keystone Symposia HIV Pathogenesis Conference

SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced that it presented preclinical results for ANX-201, the Company's broad-spectrum antiviral product candidate at the Keystone Symposia HIV Pathogenesis Conference in Banff, Alberta on March 30, 2008. The preclinical results demonstrate a unique resistance profile for ANX-201 and suggest suppression of resistance to nucleoside reverse transcriptase inhibitors (NRTIs), a commonly used class of drugs to treat HIV. The HIV Pathogenesis Conference is part of the Keystone Symposia Global Health Series, which is supported by the Bill & Melinda Gates Foundation. The poster presentation entitled "The pyrophosphate analogue thiophosphonoformic acid confers a favorable HIV resistance profile," was presented by Shani Waninger, Ph.D., associate director for research and development at ADVENTRX.

ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member of a new class of reverse transcriptase inhibitor (RTI) that is being developed to provide benefits for treatment-resistant HIV-infected patients. Foscarnet, the main metabolite of ANX-201, is approved by the FDA for use in immunocompromised patients with CMV retinitis and mucocutaneous acyclovir-resistant HSV infections. However, clinical use of foscarnet is limited, in part due to its intravenous administration and low oral bioavailability. In contrast, in vivo tests have demonstrated increased oral bioavailability of ANX-201, relative to foscarnet, potentially enabling oral delivery.

The preclinical data presented at the conference show that virus selected for resistance to ANX-201 develop genetic muta
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
2. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
3. IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
4. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
5. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
6. TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
8. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
9. Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema
10. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
11. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...ore, make a donation or send a Christmas Seals e-c...ewswire/ -- Millions will receive Christmas Seals ...ung Association. These decorative holiday stamps a...back to 1907 when the Lung Association led efforts...cans alive today have no vivid memories of how wid...
(Date:11/18/2008)... Influenza survey underscores that mothers need to...and Gold Medalist Kristi Yamaguchi joins initiativ...While 78 percent of mothers in the United States c...reatening disease that can strike anyone, only hal...ted this season, according to a new survey from th...
(Date:11/13/2008)...ments Prior to Surgery, ARLINGTON HEIGHTS, Ill., ...nutrition before surgery in massive weight loss pa...decrease surgical complications, accelerate,wound ...ergy levels,according to a study in the December ...e official medical journal of the American Society...
(Date:11/12/2008)...son, Marilyn & James Simons and,Sherry Lansing at ... J. Craig Venter,Ph.D....titute (JCVI), was,awarded the Double Helix Medal ...ber 6th at a gala event in New York City., Dr. Ve.... James D.,Watson for making each of their individ...
Breaking Medicine Technology:American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6Plastic Surgeons Warn of Malnutrition in Body Contouring Patients 2J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2Nutrition 21 Introduces New Product 3A Iceland Health Skin Rejuvenation 28TM 29 22033 1Nutrition 21 Introduces New Product 3A Iceland Health Skin Rejuvenation 28TM 29 22033 2Nutrition 21 Introduces New Product 3A Iceland Health Skin Rejuvenation 28TM 29 22033 3Ease of Use and Intuitive Nature of the DATATRAK eClinical 28TM 29 Platform Allows for Further Operational Efficiencies 22030 1Ease of Use and Intuitive Nature of the DATATRAK eClinical 28TM 29 Platform Allows for Further Operational Efficiencies 22030 2Ease of Use and Intuitive Nature of the DATATRAK eClinical 28TM 29 Platform Allows for Further Operational Efficiencies 22030 3Ease of Use and Intuitive Nature of the DATATRAK eClinical 28TM 29 Platform Allows for Further Operational Efficiencies 22030 4Chicos Hosts Jacket Design Contest to Benefit Charity 22027 1Chicos Hosts Jacket Design Contest to Benefit Charity 22027 2Pharsight to Present on Literature Based Disease Modeling Approaches at AAPS National Biotechnology Conference 6035 1Pharsight to Present on Literature Based Disease Modeling Approaches at AAPS National Biotechnology Conference 6035 2
...lynx today announced positive,interim results from... programme, ALX-0081, an anti-thrombotic treatment... therapeutic,Nanobody® targeting von Willebran...bosis in patients with acute coronary,syndrome. , ...d to assess,safety, tolerability and pharmacokinet...
...n with at least three sites of,cellular atypia in ...han average women to develop breast cancer, accord... study of women with atypical,hyperplasia. The fin...rnal of Clinical Oncology., Several previous studi...ed atypia) in breast tissue is a major risk factor...
Other Medicine Technology:Ablynx Announces Interim Results of First Nanobody Phase I Study of,ALX-0081 (ANTI-VWF) 2Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia 2Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast,Cancer Risk Prediction in Women with Atypia 3
(Date:11/21/2008)... do not cause genetic damage that can lead to dise... -- Two popular medications for treating attention...e genetic damage linked to an increased risk for d..., done by researchers at Duke University Medical C...ers a previous one that reported biomarkers associ...
(Date:11/21/2008).../ -- In a statewide survey, 33 physicians credenti...y at Presbyterian Hospital of Dallas were honored ... Super Doctors ." , , Each year, the publis... Media, Inc. to survey more than 38,000 medical pr...you needed medical care, which doctor would you ch...
(Date:11/21/2008)...wswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: ...s to the global orthopedic device industry and oth...Moore, President and Chief Executive Officer, and ...ncial Officer, are scheduled to present at the 20t...he New York Palace Hotel on Wednesday, December 3,...
(Date:11/21/2008)...he University of Texas M. D. Anderson Cancer Cente...o eradicate breast cancer in Panama through the Pa... of the Americas today at an event with Laura Bush...Fernndez de Torrijos, the First Lady of Panama. ...he U.S. Department of State and Susan G. Komen for...
Breaking Medicine News(10 mins):Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research extends to Panama 2
...e cancer puts men at increased risk for diabetes a...servational study published in the// Sept. 20 Jour...er have high five-year survival rates, but they al...rtality than healthy men,” says study author Nancy...
...and Chile announced a tax on airline tickets to ra...ients who cannot afford them//. Representatives fr...Chirac of France and Luis Ignacio Lula da Silva of...ment at the UN. UN Secretary General Kofi Annan an...
...s revealed that Maori are almost twice as likely t...y to suffer// from mental disorder generally than ...Health Ministry has been the first to shed light o... disorders among different ethnic groups in this c...
...t increased levels of lipoprotein(a)are linked wit...healthy women according to Boston-based investigat...ralized screening of lipoprotein(a) in the populat...igh levels were associated with cardiovascular ris...
Other Medicine News:Health News:Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease 2Health News:High lipoprotein Levels in women Linked to Cardiovascular Risk 2
...dus laser lens design with Volk exclusive Double A...ion viewing and treatment of the optic nerve head ...heric optics provide improved performance over exi...mes standard with LaserWindow® for optimal las...
...Laser Lens affords the practitioner a direct uprig...izing a unique solid methyl methacrylate optic wit...erior, this special optical design eliminates fila...us lenses. Available in Volk's exclusive ANF+ (Adv...
...® is excellent for critically evaluating and t...from macular degeneration, retinal vascular occlus...ic retinopathy and other retinal conditions. It is...ns providing excellent magnification combined with...
...s designed for focal laser therapy and mid-to-far ...sign presents a realistic contour of the retinal c...f the entire posterior pole extending to the equat...c movement on the globe, therefore increasing its ...
Medicine Products: